187 related articles for article (PubMed ID: 10631371)
1. MDM2/p53 protein expression in the development of colorectal adenocarcinoma.
Abdel-Fattah G; Yoffe B; Krishnan B; Khaoustov V; Itani K
J Gastrointest Surg; 2000; 4(1):109-14. PubMed ID: 10631371
[TBL] [Abstract][Full Text] [Related]
2. Expression of mdm2 and p53 in epithelial neoplasms of the colorectum.
Hao XP; Günther T; Roessner A; Price AB; Talbot IC
Mol Pathol; 1998 Feb; 51(1):26-9. PubMed ID: 9624416
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas.
Broll R; Stark A; Windhövel U; Best R; Strik MW; Schimmelpenning H; Schwandner O; Kujath P; Bruch HP; Duchrow M
Eur J Cancer; 1999 Jul; 35(7):1083-8. PubMed ID: 10533452
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas.
Magrisso IJ; Richmond RE; Carter JH; Pross CB; Gilfillen RA; Carter HW
Lab Invest; 1993 Dec; 69(6):674-81. PubMed ID: 8264230
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas.
Valassiadou KE; Stefanaki K; Tzardi M; Datseris G; Georgoulias V; Melissas J; Tsiftsis DD; Delides G; Kanavaros P
Anticancer Res; 1997; 17(4A):2571-6. PubMed ID: 9252682
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance.
Baretton GB; Diebold J; Christoforis G; Vogt M; Müller C; Dopfer K; Schneiderbanger K; Schmidt M; Löhrs U
Cancer; 1996 Jan; 77(2):255-64. PubMed ID: 8625232
[TBL] [Abstract][Full Text] [Related]
7. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
8. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival.
Kasper HU; Schneider-Stock R; Mellin W; Günther T; Roessner A
Pathol Res Pract; 1999; 195(12):815-20. PubMed ID: 10631716
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 expression in colorectal tumours. Correlation with p53, mdm-2, Rb proteins and proliferation indices.
Goussia AC; Ioachim E; Agnantis NJ; Mahera M; Tsianos EV
Histol Histopathol; 2000 Jul; 15(3):667-72. PubMed ID: 10963109
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
Koga T; Hashimoto S; Sugio K; Yoshino I; Nakagawa K; Yonemitsu Y; Sugimachi K; Sueishi K
Int J Cancer; 2001 Jul; 95(4):232-9. PubMed ID: 11400116
[TBL] [Abstract][Full Text] [Related]
11. mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer.
Paradiso A; Ranieri G; Simone G; Silvestris N; Costa A; De Lena M; Leone A; Vallejo C; Lacava J
Oncology; 2002; 62(3):278-85. PubMed ID: 12065876
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinicopathologic significance of TUFM and p53 for the normal-adenoma-carcinoma sequence in colorectal epithelia.
Xi HQ; Zhang KC; Li JY; Cui JX; Zhao P; Chen L
World J Surg Oncol; 2017 Apr; 15(1):90. PubMed ID: 28449687
[TBL] [Abstract][Full Text] [Related]
13. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
14. No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis.
Blok P; Craanen ME; Dekker W; Offerhaus GJ; Tytgat GN
J Pathol; 1998 Sep; 186(1):36-40. PubMed ID: 9875138
[TBL] [Abstract][Full Text] [Related]
15. Mdm2 and the p53 pathway in human pituitary adenomas.
Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
[TBL] [Abstract][Full Text] [Related]
16. p53 and mdm2 expression in colorectal carcinoma: a correlative analysis with clinical staging and histological parameters.
Das P; Vaiphei K; Jain D; Wig JD
Int J Surg Pathol; 2007 Oct; 15(4):335-45. PubMed ID: 17913939
[TBL] [Abstract][Full Text] [Related]
17. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of Mdm2 and p53 in feline mammary gland tumors.
Nakano M; Wu H; Taura Y; Inoue M
J Vet Med Sci; 2006 May; 68(5):421-5. PubMed ID: 16757883
[TBL] [Abstract][Full Text] [Related]
19. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
20. Fhit, Mlh1, P53 and phenotypic expression in the early stage of colorectal neoplasms.
Yasugi A; Yashima K; Hara A; Koda M; Kawaguchi K; Harada K; Andachi H; Murawaki Y
Oncol Rep; 2008 Jan; 19(1):41-7. PubMed ID: 18097574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
